Inventor
ZHIQIANG AN
Inventor
US
Overview
Patents· 17 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
C07KPeptides22%
A61KPreparations for medical, dental or toiletry purposes21%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
C12NMicroorganisms or enzymes8%
C12YEnzymes4%
C07CAcyclic or carbocyclic compounds3%
C07DHeterocyclic compounds3%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds3%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
PatentTitleYear
12,596,122LILRB2 antibodies and uses thereof202612,570,710Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer202612,503,500Connexin 43 (Cx43) hemichannel-binding antibodies202512,331,110Monoclonal antibodies against endotrophin and the use thereof202512,331,130DDR1 antibodies and uses thereof202512,202,895LILRB4 antibodies and uses thereof202512,152,071EGFL6 specific monoclonal antibodies and methods of their use202412,084,403Linkers for antibody drug conjugates202412,037,390Leptin antibodies and method of reducing leptin202411,912,758Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel202411,906,519Methods for identifying LILRB-blocking antibodies202411,760,799Leptin antibodies202311,629,122Linkers for antibody drug conjugates202311,498,963Anti-LILRB antibodies and their use in detecting and treating cancer202211,377,491Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer202211,230,591CMV neutralizing antigen binding proteins202211,174,320HER3 specific monoclonal antibodies for diagnostic and therapeutic use2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to UNIV TEXAS (16)· patent assignee history
2021–2026Based in US· patent location history
2022Patents assigned to MERCK SHARP & DOHME (1)· patent assignee history
2025–2026Patents assigned to IMMUNE ONC THERAPEUTICS INC (2)· patent assignee history
2025Patents assigned to UNIV GEORGE WASHINGTON (1)· patent assignee history
2026Patents assigned to THE BOARD OF REGENTS OF THE UNIV OF TEXAS SYSTEM (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| UNIV TEXAS | 16 | 2021–2026 |
| IMMUNE ONC THERAPEUTICS INC | 2 | 2025–2026 |
| MERCK SHARP & DOHME | 1 | 2022 |
| THE BOARD OF REGENTS OF THE UNIV OF TEXAS SYSTEM | 1 | 2026 |
| UNIV GEORGE WASHINGTON | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 17 | 2021–2026 |